RAC is rare even on an international level. I think CU6 is probably closest to RAC on the ASX, but it comes with a lot more clinical risk. Generally biotechs with low clinical risk are chasing small markets, RAC is highly unusual in chasing massive markets with a low clinical risk asset. It is so unusual that not many investors actually get what is in front of them when they look at RAC.
Add to My Watchlist
What is My Watchlist?
